Whalesbook
Transaction Details
Pharmaids Pharmaceuticals has sold its step-down subsidiary, Siri Labvivo Diet Private Limited, for ₹3.00 lakh. The transaction was completed on March 27, 2026, and was conducted through Pharmaids' material subsidiary, Adita Bio Sys Private Limited.
Limited Financial Impact
The sale of Siri Labvivo Diet Private Limited is unlikely to have a significant impact on Pharmaids Pharmaceuticals' overall financial performance or strategic direction. The subsidiary contributed minimally to the group's consolidated financials, accounting for 0.73% of revenue and a negative ₹89.11 Lakh networth contribution (representing -1.62% of the group's networth) as of March 31, 2025.
Recent Corporate Activity
Pharmaids Pharmaceuticals, operating as a CRDMO player, has been active with significant corporate developments. In 2024, the company acquired a 99.86% stake in Adita Bio Sys Private Limited, a preclinical contract research organization, establishing it as a key subsidiary. Additionally, an open offer concerning Pharmaids Pharmaceuticals took place around September 2025, signaling potential shifts in shareholding. Throughout 2025, the company also saw several executive appointments and senior management changes.
Subsidiary Status Update
Following the sale, Siri Labvivo Diet Private Limited is no longer a subsidiary of Adita Bio Sys Private Limited. Consequently, it has ceased to be a step-down subsidiary of Pharmaids Pharmaceuticals Limited. Its financial results will no longer be included in Pharmaids' consolidated statements.
Ongoing Financial Challenges
Pharmaids Pharmaceuticals continues to face significant financial headwinds. The company reported persistent net losses for four consecutive quarters ending December 2025. It has maintained a negative Return on Equity (ROE) for three consecutive years, with an overall declining earnings trend. High interest expenses, making up 10.73% of operating revenues, and substantial employee costs at 67.68% of operating revenues, further strain profitability.
Industry Peers
Pharmaids Pharmaceuticals operates in the pharmaceutical and CRDMO sector. Its major listed peers include Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Lupin Ltd., and Dr. Reddy's Laboratories Ltd. These companies operate on a significantly different scale and financial footing compared to Pharmaids.
Investor Watchlist
Investors will be monitoring Pharmaids Pharmaceuticals' progress in achieving profitability amid its ongoing losses. Key areas to track include any strategic realignments, the impact of the recent open offer on shareholding, and the effectiveness of management in navigating the company's financial challenges and focusing on its core CRDMO and specialty chemical businesses.